secwatch.observer — SEC 8-K summary
======================================

Issuer:     Virpax Pharmaceuticals, Inc. (—)
CIK:        0001708331
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0001213900-24-025754
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virpax FY2023 operating loss narrows to $15.2M; cash at $9.1M
-------------------------------------------------------------

- Operating loss of $15.2M vs $21.7M in 2022; R&D expenses halved to $5.1M.
- Cash and cash equivalents $9.1M at Dec 31, 2023, down from $19.0M a year earlier.
- Regained Nasdaq compliance on March 18, 2024, after 1-for-10 reverse stock split effective March 1.
- Litigation settlement with Sorrento/Scilex approved by bankruptcy court; initial payment made March 18, 2024.
- CEO change: Anthony Mack resigned Nov 17, 2023; Gerald Bruce appointed CEO and Eric Floyd Chairman.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708331/000121390024025754/0001213900-24-025754-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708331/000121390024025754/ea0202550-8k_virpax.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-025754

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer